Autres langues BriaCell Therapeutics Corp. Nasdaq

Actions

BCTX

CA1079303071

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:59:30 28/09/2026			Varia. 5j.	Varia. 1 janv.
4,040 ^USD	-6,37 %		-0,60 %	-41,98 %

14/09	BriaCell Therapeutics Corp reçoit une septième recommandation positive consécutive du DSMB pour son étude pivot de Phase 3 Bria-ABC sur le Bria-IMT associé à un inhibiteur de point de contrôle immunitaire	CI
11/09	Neonc Technologies Holdings, Briacell Therapeutics et Oncolytics Biotech annoncent des avancées cliniques et réglementaires dans les cancers du cerveau, du sein et colorectal	CI

Autres langues

15/09	Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
14/09	Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
14/09	BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor
11/09	Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer
09/09	BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
08/09	BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center
08/09	BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
02/09	Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.
02/09	Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.
02/09	Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.
02/09	Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.
02/09	Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.
24/08	BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+
24/08	BriaCell Therapeutics : Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)
24/08	BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
05/08	BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study
05/08	Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer
05/08	BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
16/07	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study
16/07	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT
16/07	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer
16/07	BriaCell Therapeutics : Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer
16/07	BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
15/07	BriaCell Therapeutics : Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)
15/07	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™